SGX945 FDA Approval Status
FDA Approved: No
Brand name: SGX945
Generic name: dusquetide
Company: Soligenix, Inc.
Treatment for: Behcet's Disease
SGX945 (dusquetide) is an innate defense regulator (IDR) in development for the treatment of oral lesions of Behçet's Disease.
- Behçet's Disease is an inflammatory disorder of the blood vessels characterized by mouth sores, skin rashes and lesions, genital sores, leg ulcers, and eye inflammation. It is thought to be an autoimmune disease with both genetic and environmental factors.
- Dusquetide works by modulating the innate immune system and influencing the body’s response to injury and infection by promoting anti-inflammatory, anti-infective, and tissue-healing properties.
- Dusquetide is also being studied as SGX942 for the treatment of Severe Oral Mucositis (SOM) and SGX943 for the treatment of melioidosis.
Development timeline for SGX945
| Date | Article |
|---|---|
| Jan 8, 2024 | FDA Grants Soligenix Fast Track Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
